Business Context and Reporting Period
Company: DENTSPLY International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: The world's largest manufacturer of professional dental products, operating in over 120 countries. The company serves the professional dental market with products including dental equipment, supplies, implants, and orthodontics. Approximately 98% of sales are derived from professional dental products.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2006 |
Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2006 |
Six Months Ended June 30, 2005 |
|---|---|---|---|---|
| Net Sales | $472,444 | $444,834 | $903,440 | $851,809 |
| Gross Profit | $242,154 | $227,283 | $462,290 | $436,224 |
| Operating Income | $86,592 | $81,135 | $156,600 | $151,260 |
| Net Income | $59,316 | $57,893 | $109,320 | $106,942 |
| Diluted EPS | $0.37 | $0.35 | $0.68 | $0.65 |
| Cash Flow from Operations | N/A | N/A | $92,668 | $65,128 |
| Cash and Equivalents | $475,417 | N/A | $475,417 | N/A |
| Total Debt (Current + Long-term) | $802,024 | N/A | $802,024 | N/A |
Note: Debt figures represent the sum of "Notes payable and current portion of long-term debt" and "Long-term debt" as of June 30, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.2% ($27.6 million) for the quarter and 6.1% ($51.6 million) for the six months compared to the prior year. Excluding precious metal content, internal growth was 5.2% for the quarter and 5.8% for the six months.
- Profitability: Net income rose 2.5% for the quarter and 2.2% for the six months. Gross profit margins remained stable at approximately 51.3% (quarter) and 51.2% (six months) of total sales.
- Accounting Changes: The company adopted SFAS No. 123R (Share-Based Payment) on January 1, 2006. This resulted in the recognition of $4.2 million in stock-based compensation expense for the quarter and $8.5 million for the six months, which was not expensed in the comparable 2005 periods.
- Restructuring Costs: The company recorded $2.6 million in restructuring costs for the quarter and $7.3 million for the six months, primarily related to the closure of a pharmaceutical manufacturing facility in Chicago and consolidation of U.S. production facilities. This compares to a net income of $0.2 million in restructuring for the quarter and $40,000 for the six months in 2005.
- Interest Expense: Interest expense decreased significantly to $2.4 million for the quarter (from $4.4 million in 2005) and $4.5 million for the six months (from $10.8 million in 2005), driven by lower average debt levels and higher cash balances.
Guidance, Outlook, and Risks
- Outlook: Management targets a long-term sustainable internal growth rate of 4-6%. For 2006, the company expects to introduce 20 to 25 new products. Capital expenditures are expected to range between $50 million and $60 million for the full year.
- Restructuring Outlook: The company expects additional pre-tax restructuring charges of $1 million to $3 million for the remainder of 2006 related to the Chicago facility closure.
- Supply Chain Risks: The closure of the Chicago pharmaceutical facility has caused supply disruptions for injectable dental anesthetic products. While contract manufacturing relationships are in place, there is no assurance of adequate future supply due to a limited number of suppliers.
- Legal Proceedings:
- Antitrust: An injunction prevents the company from restricting tooth dealers from adding competitive lines in the U.S. following a Department of Justice lawsuit.
- Product Liability: A class action regarding "Advance(R)" cement (166 dentists opted in) and a certified class action regarding "Cavitron(R)" ultrasonic scalers are pending. The company is preparing a motion for decertification in the Cavitron case.
- Market Risks: The company is exposed to foreign currency exchange rates, interest rates, and commodity prices (specifically precious metals). It utilizes derivatives to hedge these risks.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the full-year impact of SFAS No. 123R adoption on net income and EPS, as $8.5 million was expensed in the first half of 2006 alone.
- Restructuring Completion: Monitor the execution of the Chicago facility closure and the associated $1-3 million in remaining charges for the rest of 2006.
- Supply Chain Stability: Assess the long-term reliability of contract manufacturers for injectable anesthetics following the shutdown of the internal Chicago facility.
- Legal Exposure: Track the status of the "Advance(R)" cement and "Cavitron(R)" class action lawsuits, particularly the motion for decertification in the latter.
- Debt Maturity: Note that $560.5 million of long-term borrowings are due within the next twelve months; verify the company's plan to refinance this via its revolving credit facility.